IS2839B - 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor" - Google Patents

4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor"

Info

Publication number: IS2839B
Authority: IS; Iceland
Prior art keywords: methoxypyrid; pyrazolo; butylamino; enantiomers; triazine
Prior art date: 2001-03-13

Application number

IS6947A

Other languages

English (en)

Other versions

IS6947A (is

Inventor

Paul J Gilligan

Original Assignee

Bristol Myers Squibb Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-13

Filing date

2003-09-10

Publication date

2013-06-15

2003-09-10 Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co

2003-09-10 Publication of IS6947A publication Critical patent/IS6947A/is

2013-06-15 Publication of IS2839B publication Critical patent/IS2839B/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Addiction (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Virology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)

IS6947A 2001-03-13 2003-09-10 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor" IS2839B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27540301P	2001-03-13	2001-03-13
PCT/US2002/006837 WO2002072202A1 (en)	2001-03-13	2002-03-06	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Publications (2)

Publication Number	Publication Date
IS6947A IS6947A (is)	2003-09-10
IS2839B true IS2839B (is)	2013-06-15

Family

ID=23052141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6947A IS2839B (is)	2001-03-13	2003-09-10	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor"

Country Status (35)

Country	Link
US (4)	US20030125330A1 (is)
EP (1)	EP1368094B1 (is)
JP (1)	JP4549630B2 (is)
KR (1)	KR100875595B1 (is)
CN (1)	CN100427093C (is)
AR (1)	AR032986A1 (is)
AT (1)	ATE355102T1 (is)
AU (1)	AU2002245605B2 (is)
BG (1)	BG66331B1 (is)
BR (1)	BR0208357A (is)
CA (1)	CA2440553C (is)
CY (1)	CY1106607T1 (is)
CZ (1)	CZ20032481A3 (is)
DE (1)	DE60218434T2 (is)
DK (1)	DK1368094T3 (is)
EE (1)	EE05433B1 (is)
ES (1)	ES2282401T3 (is)
GE (1)	GEP20053608B (is)
HR (1)	HRP20030822B1 (is)
HU (1)	HU229317B1 (is)
IL (2)	IL157615A0 (is)
IS (1)	IS2839B (is)
MX (1)	MXPA03008185A (is)
MY (1)	MY146935A (is)
NO (1)	NO328580B1 (is)
NZ (1)	NZ528207A (is)
PL (1)	PL208278B1 (is)
PT (1)	PT1368094E (is)
RS (1)	RS50863B (is)
RU (1)	RU2292347C2 (is)
SK (1)	SK287603B6 (is)
TW (1)	TWI257388B (is)
UA (1)	UA74634C2 (is)
WO (1)	WO2002072202A1 (is)
ZA (1)	ZA200306995B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094782B1 (en) *	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
US20030125330A1 (en) *	2001-03-13	2003-07-03	Gilligan Paul J.	4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AR041470A1 (es)	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7329658B2 (en) *	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) *	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7041671B2 (en) *	2003-04-02	2006-05-09	Pfizer Inc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7056920B2 (en)	2003-04-04	2006-06-06	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
US7034023B2 (en)	2003-04-04	2006-04-25	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
CA2520805A1 (en) *	2003-04-15	2004-10-28	Pharmacia & Upjohn Company Llc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7208596B2 (en) *	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
AU2007297421B2 (en)	2006-09-20	2012-03-08	Eli Lilly And Company	Thiazole pyrazolopyrimidines as CRF1 receptor antagonists
JP2015516979A (ja) *	2012-04-23	2015-06-18	ホルスボールマッシュマイヤーニューロケミーゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒＮｅｕｒｏｃｈｅｍｉｅＧｍｂｈ	Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR102079844B1 (ko) *	2016-09-20	2020-02-20	가톨릭대학교 산학협력단	담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
CN110996943A (zh)	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
KR20240023691A (ko)	2020-08-12	2024-02-22	스프루스 바이오사이언시스 인코포레이티드	다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
WO1995010506A1 (en)	1993-10-12	1995-04-20	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
WO1997035846A1 (en)	1996-03-26	1997-10-02	Dupont Pharmaceuticals Company	Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en)	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
AU3064397A (en)	1996-05-24	1997-12-09	Dow Chemical Company, The	Process for preparing aliphatic ester compounds and alkanols
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
CA2259583C (en) *	1996-07-24	2009-11-17	Du Pont Pharmaceuticals Company	Azolo triazines and pyrimidines
PT915880E (pt)	1996-07-24	2007-12-31	Bristol Myers Squibb Pharma Co	Azol triazinas e pirimidinas
CN1227554A (zh) *	1996-08-28	1999-09-01	辉瑞大药厂	取代的6,5－杂二环衍生物
US6103737A (en)	1997-07-03	2000-08-15	Dupont Pharmaceuticals Company	Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
NZ502642A (en)	1997-07-03	2002-06-28	Du Pont Pharm Co	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
UA62972C2 (en)	1997-07-03	2004-01-15		Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
BR9814458A (pt)	1997-09-02	2001-10-23	Du Pont Pharm Co	Composto, composição farmacêutica e método de tratamento de disfunções afetivas
ATE301657T1 (de) *	1998-01-28	2005-08-15	Bristol Myers Squibb Pharma Co	Azolo-pyrimidine
US6194410B1 (en)	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
CA2326884A1 (en)	1998-04-03	1999-10-14	Dupont Pharmaceuticals Company	Thiazolo¬4,5-d\|pyrimidines and pyridines as corticotropin releasing factor (crf) antagonists
US6124463A (en)	1998-07-02	2000-09-26	Dupont Pharmaceuticals	Benzimidazoles as corticotropin release factor antagonists
AU770377B2 (en) *	1999-05-21	2004-02-19	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
US20030125330A1 (en) *	2001-03-13	2003-07-03	Gilligan Paul J.	4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

2002
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 EP EP02713776A patent/EP1368094B1/en not_active Expired - Lifetime
- 2002-03-06 CA CA2440553A patent/CA2440553C/en not_active Expired - Fee Related
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/en not_active Ceased
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active Expired - Fee Related
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/uk unknown
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2002072202A1 (en)	2002-09-19
KR100875595B1 (ko)	2008-12-23
DE60218434T2 (de)	2007-11-08
CZ20032481A3 (cs)	2007-12-27
US20030125330A1 (en)	2003-07-03
HRP20030822A2 (en)	2004-04-30
PL368644A1 (en)	2005-04-04
HK1057182A1 (en)	2004-03-19
HU229317B1 (en)	2013-10-28
US7358252B2 (en)	2008-04-15
IS6947A (is)	2003-09-10
ATE355102T1 (de)	2006-03-15
AU2002245605B2 (en)	2006-02-02
CN100427093C (zh)	2008-10-22
DK1368094T3 (da)	2007-07-02
IL157615A0 (en)	2004-03-28
UA74634C2 (uk)	2006-01-16
DE60218434D1 (en)	2007-04-12
TWI257388B (en)	2006-07-01
US7157578B2 (en)	2007-01-02
NO328580B1 (no)	2010-03-22
RS50863B (sr)	2010-08-31
EE200300435A (et)	2003-12-15
YU71503A (sh)	2006-05-25
US20040014760A1 (en)	2004-01-22
AR032986A1 (es)	2003-12-03
CA2440553A1 (en)	2002-09-19
HRP20030822B1 (en)	2008-01-31
GEP20053608B (en)	2005-09-12
SK287603B6 (sk)	2011-03-04
CA2440553C (en)	2010-06-08
SK11572003A3 (sk)	2004-02-03
US20080139567A1 (en)	2008-06-12
EP1368094B1 (en)	2007-02-28
MXPA03008185A (es)	2004-01-29
NZ528207A (en)	2006-02-24
HUP0303480A2 (hu)	2004-01-28
BG66331B1 (bg)	2013-06-28
JP4549630B2 (ja)	2010-09-22
RU2292347C2 (ru)	2007-01-27
HUP0303480A3 (en)	2005-12-28
EE05433B1 (et)	2011-06-15
KR20030080086A (ko)	2003-10-10
NO20034023L (no)	2003-09-11
CN1509196A (zh)	2004-06-30
PL208278B1 (pl)	2011-04-29
ES2282401T3 (es)	2007-10-16
IL157615A (en)	2009-09-01
NO20034023D0 (no)	2003-09-11
US20070054913A1 (en)	2007-03-08
CY1106607T1 (el)	2012-01-25
PT1368094E (pt)	2007-05-31
US7662817B2 (en)	2010-02-16
MY146935A (en)	2012-10-15
EP1368094A4 (en)	2004-03-31
EP1368094A1 (en)	2003-12-10
BG108189A (bg)	2004-09-30
RU2003130093A (ru)	2005-03-20
ZA200306995B (en)	2004-09-08
JP2004530662A (ja)	2004-10-07
BR0208357A (pt)	2004-06-29

Publication	Publication Date	Title
IS2839B (is)	2013-06-15	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor"
ATE530530T1 (de)	2011-11-15	Diaminopyrimidincarbonsäureamidderivat
NO20032892L (no)	2003-11-18	4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
DE50210707D1 (de)	2007-09-27	Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
ITRM20030521A1 (it)	2004-05-13	Procedimento di bloccaggio di sovvenzionamento attraverso l'etere.
IL155999A0 (en)	2003-12-23	Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
DE60201437D1 (de)	2004-11-04	2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten
IS7314A (is)	2004-06-16	5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf
EE05223B1 (et)	2009-10-15	Triasoloprimidiini hendid, meetod nende valmistamiseks ning nende kasutamine
EE05362B1 (et)	2010-12-15	Aniliini derivaadid, mis on kasulikud kui fosfodiesteraas 4 inhibiitorid
DK1250328T3 (da)	2006-10-30	Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf
ATE303388T1 (de)	2005-09-15	Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
ZA200500065B (en)	2006-03-29	Crystalline 2,5,-dione-3-(1-methyl-1H-indol-3-yl)-Ä1-(pyridin-2-ylmethyl)piperidin-4-ylÜ-1H-indol-3-ylÜ-1H-pyrrole mono-hydrochloride
DK1177166T3 (da)	2008-06-16	Fremgangsmåde til fremstilling af (1R,2S,4R)-(-)-2(2'-N,N-dimenthylamino-etoxy)-2-phenyl-1,7,7-tri-mehtyl.bicyclo-2.2.1-heptan og farmaceutisk acceptable syreadditionssalte deraf
PL375263A1 (en)	2005-11-28	2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
DE60215804D1 (de)	2006-12-14	4-aminopyrimidine derivate
DK1027891T3 (da)	2005-05-09	Neuropeptid-Y-antagonister
FI20012371L (fi)	2003-06-04	Menetelmä liitoksen vapauttamiseksi
IL164377A0 (en)	2005-12-18	Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
AR027974A1 (es)	2003-04-23	1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
DK1497256T3 (da)	2010-09-27	Substituerede 1,5-diaminopentan-3-ol-forbindelser
DE60142063D1 (de)	2010-06-17	(2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung
ES1051471Y (es)	2002-12-01	Sandalia multiforme perfeccionada
PL353421A1 (en)	2003-10-20	New derivatives of symmetrical 1,3,5-triazine
ES1050833Y (es)	2002-09-16	Pieza para la union de tablas de entarimados de madera.